Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Core Viewpoint - Soligenix, Inc. announced the publication of a clinical summary for HyBryte™ in the journal "Expert Opinion on Investigational Drugs," highlighting its potential as a treatment for cutaneous T-cell lymphoma (CTCL) [1][2]. Clinical Trials and Efficacy - HyBryte™ (synthetic hypericin) has shown promising results in clinical trials, with a unique mechanism of action and an excellent safety profile, positioning it as a potential first-line treatment for early-stage CTCL [3][4]. - In the Phase 3 FLASH trial, 16% of patients treated with HyBryte™ achieved at least a 50% reduction in lesions compared to 4% in the placebo group, demonstrating statistical significance (p=0.04) [5]. - The second treatment cycle showed a 40% response rate in patients receiving 12 weeks of HyBryte™ treatment, significantly higher than the placebo group [6]. - In the optional third treatment cycle, 49% of patients who received HyBryte™ throughout all cycles demonstrated a positive treatment response [7]. Safety Profile - HyBryte™ is noted for its safety, with no evidence of systemic absorption or DNA damage, making it a safer alternative to current therapies that carry significant side effects [8]. - The treatment has been well tolerated across all three treatment cycles, with no serious safety issues reported [7][8]. Regulatory Status and Future Studies - HyBryte™ has received orphan drug and fast track designations from the FDA, and orphan designation from the EMA, facilitating its development for CTCL [4]. - A second confirmatory Phase 3 study, FLASH2, is underway, with an interim analysis expected in Q2 2026, aiming to replicate the successful design of the first FLASH study [9][10]. - The FDA has awarded a $2.6 million Orphan Products Development grant to support an investigator-initiated study for expanded treatment of HyBryte™ in early-stage CTCL [12]. Market Context - CTCL is a rare form of non-Hodgkin's lymphoma affecting approximately 31,000 individuals in the U.S. and 38,000 in Europe, with no current approved front-line therapies available [13][14]. - Soligenix is focused on addressing unmet medical needs in rare diseases, with HyBryte™ as a key product in its pipeline [14].